// App-Quantinova.ai

2817 : Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Researchers

Presenter

  • Geoffrey L Uy

Principal Investigators

  • Stephanie Christ

  • Ibrahim Aldoss

  • Michael T. Byrne

  • Harry P. Erba

  • Martha L. Arellano

  • Matthew C Foster

  • John E. Godwin

  • Farhad Ravandi

  • Peter H. Sayre

  • Anjali S Advani

  • Matthew J. Wieduwilt

  • Ashkan Emadi

  • Laura C. Michaelis

  • Patrick J. Stiff

  • Martin Wermke

  • Norbert Vey

  • Patrice Chevalier

  • Emmanuel Gyan

  • Christian Recher

  • Fabio Ciceri

  • Matteo Giovanni Carrabba

  • Antonio Curti

  • Geert Huls

  • Max S. Topp

  • Mojca Jongen-Lavrencic

  • John Muth

  • Teia Curtis

  • Mary Beth Collins

  • Erin Timmeny

  • Kuo Guo

  • Jian Zhao

  • Kathy Tran

  • Patrick Kaminker

  • Priyanka Patel

  • Ouiam Bakkacha

  • Kenneth Jacobs

  • Maya Kostova

  • Jennifer Seiler

  • Bob Lowenberg

  • Sergio Rutella

  • Roland B. Walter

  • Ezio Bonvini

  • Jan K Davidson-Moncada

  • John F. DiPersio

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.

  • Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.

  • Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

  • University of Alabama at Birmingham, Birmingham, AL

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC

  • Providence Medical Center, Portland, OR

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of California, San Francisco, San Francisco, CA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD

  • Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

  • Loyola University Chicago Stritch School of Medicine, Maywood, IL

  • NCT/UCC Early Clinical Trial Unit, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

  • Service -Hematologie Clinique, Institut Paoli Calmettes, Marseille, France

  • Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France

  • CHU de Tours - Hôpital Bretonneau, Tours, France

  • Service d'Hématologie,Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole,TOULOUSE,France

  • Pathology Unit, San Raffaele H. Scientific Institute, Milano, Italy

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Hematology/Oncology "L. e A. Seràgnoli", Sant’Orsola-Malpighi University Hospital, Bologna, Bologna, Italy

  • Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • MacroGenics, Inc., Rockville, MD

  • MacroGenics, Inc., Frederick, MD

  • MacroGenics, Rockville

  • MacroGenics, Inc., ROCKVILLE, MD

  • MacroGenics, Inc., Rockville, MD

  • MacroGenics, Inc., Rockville, MD

  • MacroGenics, Inc., ROCKVILLE, MD

  • MacroGenics, Inc., Rockville, MD

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • MacroGenics, Inc., Washington, DC

Locations

  • United States

  • Germany

  • France

  • Italy

  • Netherlands

  • United Kingdom

Companies

  • MacroGenics, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

Biomarkers

  • Cytokine

  • Twist-related protein 1

Drug/Treatment

  • Flotetuzumab

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved